Shockwave ™ vs Endarterectomia chirurgica per stenosi arteria femorale comune grave calcificata: confronto tra efficacia, sicurezza e risultati a lungo termine (Shockify)
The investigators hypothesize that Shockwave with DCB is non-inferior to surgical endarterectomy for common femoral artery (CFA) stenosis with regard to primary efficacy and safety endpoints. The study will challenge the current guideline that recommends common femoral endarterectomy (CFE) as the primary treatment for symptomatic CFA stenosis.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a pilot, prospective, randomized clinical trial. This trial compares patients with severe symptomatic moderate to severe calcified CFA stenosis undergoing traditional gold standard CFA endarterectomy to innovative technique of endovascular treatment using Shockwave™ Intra vascular Lithotripsy (IVL) using M5+ balloon with Drug coated balloon to achieve removal and debulking of plaque and achieve luminal gain. Patients who meet inclusion criteria will be informed and consented by a clinical coordinator if they wish to participate in the trial. If participants are candidates for surgery, they will then be randomized into one of two cohorts, receiving either Shockwave™ IVL + DCB (drug-coated balloon) procedure or a standard surgical endarterectomy. The study compares the 1-year efficacy and 6-month safety outcomes post-procedure for patients with severe, symptomatic CFA stenosis receiving Shockwave™ IVL with DCB versus surgical endarterectomy.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Texas
-
Plano, Texas, Stati Uniti, 75093
- Baylor Scott & White The Heart Hospital - Plano
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
A patient will be eligible for inclusion in this study if he or she meets all of the following criteria (confirmed by core lab):
- CFA atherosclerotic stenosis 60-100%
- Moderate to severe calcification reported on imaging
- Lifestyle-limiting intermittent claudication (IC) or chronic limb-threatening ischemia (CLTI) as described by Rutherford chronic limb ischemia (CLI) category 2-5
- Failing conservative therapy
- Operative candidate for CFE prior to enrollment
- ≥18 years of age
Exclusion Criteria:
A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:
- History of CFE or bypass in affected limb
- Thrombosis of affected CFA
- Aneurysm in the common femoral artery of target limb
- Known target lesion restenosis (re-narrowing of the artery to ≥50% following the alleviation of a previous narrowing within 3 months)
- Any preceding percutaneous cardiovascular intervention within 2 weeks
- Inability to tolerate DAPT
- Known coagulopathy or bleeding diathesis, thrombocytopenia with platelet count <100,000/µL
- Uncontrolled diabetes (HbA1c ≥10.0%)
- Non-ambulatory
- Extensive tissue loss requiring amputation or salvageable only with complex foot reconstruction or non-traditional transmetatarsal amputations
- MI within 6 weeks (defined as presumed ischemic symptoms (chest pain, ST-segment deviation and troponin higher than 2 times the upper limit of normal))
- Stroke within 3 months (defined as sudden transient or irreversible focal neurological deficit resulting from a cerebrovascular cause)
- Pregnant
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Shockwave Catheter
Shockwave™ Intravenous Lithotripsy (IVL)+ DCB (Drug Coated Balloon) |
Shockwave™ IVL + DCB procedure |
|
Comparatore attivo: surgical endarterectomy
Surgery should be performed with patch angioplasty, with or without profunda femoris endarterectomy. |
Standard CFA endarterectomy |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Revascolarizzazione della lesione target clinicamente guidata (CDTLR (rivoluzionamento ripetuto di sintomo della lesione dell'indice))
Lasso di tempo: Data della procedura a 1 anno dopo l'OP
|
Data della procedura a 1 anno dopo l'OP
|
|
|
Restenosi a ≥ 50% della lesione bersaglio sull'angiografia o l'ecografia di follow-up
Lasso di tempo: Data della procedura a 1 anno dopo l'OP
|
Data della procedura a 1 anno dopo l'OP
|
|
|
Libertà dalla morte perioperatoria
Lasso di tempo: Data della procedura a 30 giorni dopo l'OP
|
Data della procedura a 30 giorni dopo l'OP
|
|
|
Libertà dai principali eventi cardiovascolari avversi (mazza (ictus, infarto del miocardio (MI), morte cardiovascolare))
Lasso di tempo: Data della procedura a 30 giorni dopo l'OP
|
Data della procedura a 30 giorni dopo l'OP
|
|
|
Freedom from major adverse events
Lasso di tempo: Procedure date through 6 months post-op
|
|
Procedure date through 6 months post-op
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mortalità
Lasso di tempo: Data della procedura a 1 anno dopo l'OP
|
Data della procedura a 1 anno dopo l'OP
|
|
|
Trasfusione di sangue intraoperatoria> 4 minuti
Lasso di tempo: Intra-op
|
Intra-op
|
|
|
Durata procedurale (minuti)
Lasso di tempo: Intra-op
|
Intra-op
|
|
|
Durata del soggiorno (giorni)
Lasso di tempo: Data della procedura a 1 anno dopo l'OP
|
Data della procedura a 1 anno dopo l'OP
|
|
|
Anemia postoperatoria che richiede trasfusione di sangue
Lasso di tempo: Data della procedura a 30 giorni dopo l'OP
|
Data della procedura a 30 giorni dopo l'OP
|
|
|
Riammissioni
Lasso di tempo: 30 giorni dopo l'operazione, 30 giorni dopo l'incarico
|
30 giorni dopo l'operazione, 30 giorni dopo l'incarico
|
|
|
Torna in sala operatoria / suite angiografia
Lasso di tempo: 30 giorni dopo l'operazione
|
30 giorni dopo l'operazione
|
|
|
Rutherford Chronic Limb Ischemia (CLI) Category
Lasso di tempo: 30 days post-op, 3 months post-op, 6 months post-op, 1 year post-op
|
https://www.ncbi.nlm.nih.gov/books/NBK553864/table/ch20.Tab2/# Stage 0 - Asymptomatic. Stage 1 - Mild claudication - Completes treadmill exercise; Ankle Pressure (AP) after exercise >50 mmHg but at least 20 mmHg lower than resting value. Stage 2 - Moderate claudication - Between categories 1 and 3. Stage 3 - Severe claudication - Cannot complete standard treadmill exercise and AP after exercise <50 mm Hg. Stage 4 - Ischemic rest pain - Resting AP <40 mm Hg, flat or barely pulsatile ankle or metatarsal pulse volume recording (PVR); Toe Pressure (TP) < 30 mm Hg. Stage 5 - Minor tissue loss-nonhealing ulcer, focal gangrene with diffuse pedal ischemia- Resting AP < 60 mm Hg, ankle or metatarsal PVR flat or barely pulsatile; TP < 40 mm Hg Stage 6 - Major tissue loss-extending above TM level, functional foot no longer salvageable - Same as category 5 |
30 days post-op, 3 months post-op, 6 months post-op, 1 year post-op
|
|
Treatment satisfaction and quality of life (PAQ)
Lasso di tempo: Pre-op, 30 days post-op, 6 months post-op, 1 year post-op
|
Measured by the Peripheral Artery Questionnaire (PAQ), a 20-question questionnaire measuring peripheral vascular disease affect on quality of life. Questionnaires may be completed in-person or via phone call conducted by the study coordinator. |
Pre-op, 30 days post-op, 6 months post-op, 1 year post-op
|
|
Access/surgical site complications
Lasso di tempo: 30 days post-op, 6 months post-op
|
|
30 days post-op, 6 months post-op
|
|
Pneumonia (number of cases)
Lasso di tempo: Procedure date through 30 days post-op
|
Patients must meet criteria from both sections: Radiology: One definitive chest radiological exam (x-ray or CT) with at least one of the following:
Patients with underlying pulmonary or cardiac disease require two serial chest radiological exams (x-ray or CT) taken no less than 12 hours apart, but no more than 7 days apart. Signs/Symptoms/Laboratory: at least one of the following:
|
Procedure date through 30 days post-op
|
|
Prolonged intubation
Lasso di tempo: Procedure date through 30 days post-op
|
Intubation greater than 48 hours postoperatively |
Procedure date through 30 days post-op
|
|
Urinary tract infection
Lasso di tempo: Procedure date through 30 days post-op
|
Must meet one of the following TWO criteria within 30 days of the operation:
AND urine culture of >105 colonies/mL urine with no more than two species of organisms OR two of the following:
AND any of the following:
|
Procedure date through 30 days post-op
|
|
Sepsis
Lasso di tempo: Procedure date through 30 days post-op
|
The disorder spectrum spans from relatively mild physiologic abnormalities to septic shock. The most significant level is reported using the following criteria: SIRS (Systemic Inflammatory Response Syndrome), clinically recognized by the presence of two or more of the following in the same time frame: Temp >38 degrees C or 90 bpm RR >20 breaths/min or PaCO2 12,000 cell/mm3, 10% immature (band) forms anion gap acidosis. Report if the patient has clinical signs and symptoms of SIRS listed above and meets either A or B: A. One of the following:
B. Suspected pre-operative infection or bowel infarction leading to the surgical procedure. Procedural findings must confirm this suspected diagnosis with one or more of the following:
|
Procedure date through 30 days post-op
|
|
Septic shock
Lasso di tempo: Procedure date through 30 days post-op
|
Report this variable if the patient has sepsis AND documented organ and/or circulatory dysfunction. Examples of organ dysfunction include: oliguria, acute alteration in mental status, acute respiratory distress. Examples of circulatory dysfunction include: hypotension, requirement of inotropic or vasopressor agents. The presence of pneumatosis along with the presence of SIRS is assigned. |
Procedure date through 30 days post-op
|
|
Graft failure
Lasso di tempo: Procedure date through 30 days post-op
|
Mechanical failure of an extracardiac graft or prosthesis including myocutaneous flaps and skin grafts requiring return to the operating room, interventional radiology or a balloon angioplasty within 30 days of the operation. |
Procedure date through 30 days post-op
|
|
Cardiac arrest
Lasso di tempo: Procedure date through 30 days post-op
|
The absence of cardiac rhythm or presence of chaotic cardiac rhythm, intraoperatively or postoperatively, which results in a cardiac arrest requiring the initiation of CPR, which includes chest compressions. Patients are included who are in a pulseless VT or Vfib in in which defibrillation is performed and PEA arrests requiring chest compressions. Patients with automated implantable cardioverter defibrillator (AICD) that fire but the patient has no loss of consciousness should be excluded. |
Procedure date through 30 days post-op
|
|
Myocardial infarction
Lasso di tempo: Procedure date through 30 days post-op
|
Documentation of one or more of the following changes indicative of acute MI:
|
Procedure date through 30 days post-op
|
|
Acute kidney injury
Lasso di tempo: Procedure date through 30 days post-op
|
In a patient who did not require dialysis preoperatively, worsening of renal dysfunction postoperatively requiring hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration, or ultrafiltration |
Procedure date through 30 days post-op
|
|
Dialysis
Lasso di tempo: Procedure date through 30 days post-op
|
Initiation of hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration or ultrafiltration in a patient not previously on said therapy preoperatively |
Procedure date through 30 days post-op
|
|
Deep vein thrombosis
Lasso di tempo: Procedure date through 30 days post-op
|
New diagnosis of blood clot or thrombus within the venous system (superficial or deep) which may be coupled with inflammation and requires treatment. Must be noted within 30 days after the principal operative procedure AND one of the following A or B below: A.New Diagnosis of a [new] venous thrombosis (superficial or deep), confirmed by a duplex, venogram, CT scan, or any other definitive imaging modality (including direct pathology examination such as autopsy) AND the patient must be treated with anticoagulation therapy and/or placement of a vena cava filter or clipping of the vena cava, or the record indicates that treatment was warranted but there was no additional appropriate treatment option available. B. As per (A) above, but the patient or decisionmaker has refused treatment. There must be documentation in the medical record of the [patient's] refusal of treatment. |
Procedure date through 30 days post-op
|
|
Pulmonary embolism
Lasso di tempo: Procedure date through 30 days post-op
|
Lodging of a blood clot in the pulmonary artery with subsequent obstruction of blood supply to the lung parenchyma. The blood clots usually originate from the deep leg veins or pelvic venous system. Since there are not always preoperative studies proving that a clot or thrombus was not present preoperatively, the technical specification of the variable requires only a "new diagnosis"- in other words the clot or thrombus was not previously known. A pulmonary embolism must be noted within 30 days after the principal operative procedure AND the following criteria, A AND B below: A. New diagnosis of a new blood clot in a pulmonary artery AND B. The patient has a V-Q scan interpreted as high probability of pulmonary embolism or a positive CT exam, TEE, pulmonary arteriogram, CT angiogram, or any other definitive imaging modality (including direct pathology examination such as autopsy |
Procedure date through 30 days post-op
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Sameh Sayfo, MD, Baylor Scott & White The Heart Hospital - Plano
- Investigatore principale: John Kedora, MD, Baylor Scott & White The Heart Hospital - Plano
Pubblicazioni e link utili
Pubblicazioni generali
- Adams G, Shammas N, Mangalmurti S, Bernardo NL, Miller WE, Soukas PA, Parikh SA, Armstrong EJ, Tepe G, Lansky A, Gray WA. Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study. J Endovasc Ther. 2020 Jun;27(3):473-480. doi: 10.1177/1526602820914598. Epub 2020 Apr 3.
- Stavroulakis K, Schwindt A, Torsello G, Beropoulis E, Stachmann A, Hericks C, Bollenberg L, Bisdas T. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Common Femoral Artery Atherosclerotic Disease. J Endovasc Ther. 2018 Feb;25(1):92-99. doi: 10.1177/1526602817748319. Epub 2017 Dec 18.
- Brodmann M, Werner M, Holden A, Tepe G, Scheinert D, Schwindt A, Wolf F, Jaff M, Lansky A, Zeller T. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD II. Catheter Cardiovasc Interv. 2019 Feb 1;93(2):335-342. doi: 10.1002/ccd.27943. Epub 2018 Nov 25.
- Spertus J, Jones P, Poler S, Rocha-Singh K. The peripheral artery questionnaire: a new disease-specific health status measure for patients with peripheral arterial disease. Am Heart J. 2004 Feb;147(2):301-8. doi: 10.1016/j.ahj.2003.08.001.
- Brodmann M, Werner M, Brinton TJ, Illindala U, Lansky A, Jaff MR, Holden A. Safety and Performance of Lithoplasty for Treatment of Calcified Peripheral Artery Lesions. J Am Coll Cardiol. 2017 Aug 15;70(7):908-910. doi: 10.1016/j.jacc.2017.06.022. No abstract available.
- Adams G, Soukas PA, Mehrle A, Bertolet B, Armstrong EJ. Intravascular Lithotripsy for Treatment of Calcified Infrapopliteal Lesions: Results from the Disrupt PAD III Observational Study. J Endovasc Ther. 2022 Feb;29(1):76-83. doi: 10.1177/15266028211032953. Epub 2021 Aug 12.
- Tepe G, Brodmann M, Werner M, Bachinsky W, Holden A, Zeller T, Mangalmurti S, Nolte-Ernsting C, Bertolet B, Scheinert D, Gray WA; Disrupt PAD III Investigators. Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Randomized Disrupt PAD III Trial. JACC Cardiovasc Interv. 2021 Jun 28;14(12):1352-1361. doi: 10.1016/j.jcin.2021.04.010.
- Kang JL, Patel VI, Conrad MF, Lamuraglia GM, Chung TK, Cambria RP. Common femoral artery occlusive disease: contemporary results following surgical endarterectomy. J Vasc Surg. 2008 Oct;48(4):872-7. doi: 10.1016/j.jvs.2008.05.025. Epub 2008 Jul 17.
- Kuma S, Tanaka K, Ohmine T, Morisaki K, Kodama A, Guntani A, Ishida M, Okazaki J, Mii S. Clinical Outcome of Surgical Endarterectomy for Common Femoral Artery Occlusive Disease. Circ J. 2016;80(4):964-9. doi: 10.1253/circj.CJ-15-1177. Epub 2016 Feb 19.
- Nguyen BN, Amdur RL, Abugideiri M, Rahbar R, Neville RF, Sidawy AN. Postoperative complications after common femoral endarterectomy. J Vasc Surg. 2015 Jun;61(6):1489-94.e1. doi: 10.1016/j.jvs.2015.01.024. Epub 2015 Feb 19.
- Shammas NW, Abi Doumet A, Karia R, Khalafallah R. An Overview of the Treatment of Symptomatic Common Femoral Artery Lesions with a Focus on Endovascular Therapy. Vasc Health Risk Manag. 2020 Feb 20;16:67-73. doi: 10.2147/VHRM.S242291. eCollection 2020.
- Bonvini RF, Rastan A, Sixt S, Noory E, Schwarz T, Frank U, Roffi M, Dorsaz PA, Schwarzwalder U, Burgelin K, Macharzina R, Zeller T. Endovascular treatment of common femoral artery disease: medium-term outcomes of 360 consecutive procedures. J Am Coll Cardiol. 2011 Aug 16;58(8):792-8. doi: 10.1016/j.jacc.2011.01.070.
- Linni K, Ugurluoglu A, Hitzl W, Aspalter M, Holzenbein T. Bioabsorbable stent implantation vs. common femoral artery endarterectomy: early results of a randomized trial. J Endovasc Ther. 2014 Aug;21(4):493-502. doi: 10.1583/14-4699R.1.
- Garcia LA, Lyden SP. Atherectomy for infrainguinal peripheral artery disease. J Endovasc Ther. 2009 Apr;16(2 Suppl 2):II105-15. doi: 10.1583/08-2656.1.
- Baig M, Kwok M, Aldairi A, Imran HM, Khan MS, Moustafa A, Hyder ON, Saad M, Aronow HD, Soukas PA. Endovascular Intravascular Lithotripsy in the Treatment of Calcific Common Femoral Artery Disease: A Case Series With an 18-Month Follow-Up. Cardiovasc Revasc Med. 2022 Oct;43:80-84. doi: 10.1016/j.carrev.2022.05.003. Epub 2022 May 7.
- Varcoe RL, DeRubertis BG, Kolluri R, Krishnan P, Metzger DC, Bonaca MP, Shishehbor MH, Holden AH, Bajakian DR, Garcia LA, Kum SWC, Rundback J, Armstrong E, Lee JK, Khatib Y, Weinberg I, Garcia-Garcia HM, Ruster K, Teraphongphom NT, Zheng Y, Wang J, Jones-McMeans JM, Parikh SA; LIFE-BTK Investigators. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Engl J Med. 2024 Jan 4;390(1):9-19. doi: 10.1056/NEJMoa2305637. Epub 2023 Oct 25.
- Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997 Sep;26(3):517-38. doi: 10.1016/s0741-5214(97)70045-4.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 021-263
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .